Skip to main content
Top
Published in: Supportive Care in Cancer 1/2017

01-01-2017 | Original Article

Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study

Authors: Naoki Matsuo, Tatsuya Morita, Yoshinobu Matsuda, Kenichiro Okamoto, Yoshihisa Matsumoto, Keisuke Kaneishi, Takuya Odagiri, Hiroki Sakurai, Hideki Katayama, Ichiro Mori, Hirohide Yamada, Hiroaki Watanabe, Taro Yokoyama, Takashi Yamaguchi, Tomohiro Nishi, Akemi Shirado, Shuji Hiramoto, Toshio Watanabe, Hiroyuki Kohara, Satofumi Shimoyama, Etsuko Aruga, Mika Baba, Koki Sumita, Satoru Iwase

Published in: Supportive Care in Cancer | Issue 1/2017

Login to get access

Abstract

Purpose

Although corticosteroids are widely used to relieve anorexia, information regarding the factors predicting responses to corticosteroids remains limited. The purpose of the study is to identify potential factors predicting responses to corticosteroids for anorexia in advanced cancer patients.

Methods

Inclusion criteria for this multicenter prospective observational study were patients who had metastatic or locally advanced cancer and had an anorexia intensity score of 4 or more on a 0–10 Numerical Rating Scale (NRS). Univariate and multivariate analyses were conducted to identify the factors predicting ≥2-point reduction in NRS on day 3.

Results

Among 180 patients who received corticosteroids, 99 (55 %; 95 % confidence interval [CI], 47–62 %) had a response with ≥2-point reduction. Factors that significantly predicted responses were Palliative Performance Scale (PPS) > 40 and absence of drowsiness. In addition, factors that tended to be associated with ≥2-point reduction in NRS included PS 0–3, absence of diabetes mellitus, absence of peripheral edema, presence of lung metastasis, absence of peritoneal metastasis, baseline anorexia NRS of >6, presence of pain, and presence of constipation. A multivariate analysis showed that the independent factors predicting responses were PPS of >40 (odds ratio = 2.7 [95 % CI = 1.4–5.2]), absence of drowsiness (2.6 [1.3–5.0]), and baseline NRS of >6 (2.4 [1.1–4.8]).

Conclusions

Treatment responses to corticosteroids for anorexia may be predicted by PPS, drowsiness, and baseline symptom intensity. Larger prospective studies are needed to confirm these results.
Literature
1.
go back to reference Solano JP, Gomes B, Higginson IJ (2006) A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag 31:58–69CrossRef Solano JP, Gomes B, Higginson IJ (2006) A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag 31:58–69CrossRef
2.
go back to reference Seow H, Barbera L, Dudgeon D, Howell D, Husain A, Atzema C, Sussman J, Liu Y, Earle C, Sutradhar R (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158. doi:10.1200/JCO.2010.30.7173 CrossRefPubMed Seow H, Barbera L, Dudgeon D, Howell D, Husain A, Atzema C, Sussman J, Liu Y, Earle C, Sutradhar R (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158. doi:10.​1200/​JCO.​2010.​30.​7173 CrossRefPubMed
3.
go back to reference Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1974) Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609CrossRefPubMed Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1974) Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609CrossRefPubMed
4.
go back to reference Bruera E, Roca E, Cedaro L, Carraro S, Chacon R (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754PubMed Bruera E, Roca E, Cedaro L, Carraro S, Chacon R (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754PubMed
5.
go back to reference Willox JC, Corr J, Shaw J, et al. (1984) Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 288:27CrossRef Willox JC, Corr J, Shaw J, et al. (1984) Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 288:27CrossRef
6.
go back to reference Della Cuna GR, Pellegrini A, Piazzi M (1989) Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The methylprednisolone preterminal cancer study group. Eur J Cancer Clin Oncol 25:1817–1821CrossRefPubMed Della Cuna GR, Pellegrini A, Piazzi M (1989) Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The methylprednisolone preterminal cancer study group. Eur J Cancer Clin Oncol 25:1817–1821CrossRefPubMed
7.
go back to reference Popiela T, Lucchi R, Giongo F (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. The methylprednisolone female preterminal cancer study group. Eur J Cancer Clin Oncol 25:1823–1829CrossRefPubMed Popiela T, Lucchi R, Giongo F (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. The methylprednisolone female preterminal cancer study group. Eur J Cancer Clin Oncol 25:1823–1829CrossRefPubMed
8.
go back to reference Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag 28:381–388CrossRef Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag 28:381–388CrossRef
9.
go back to reference Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M, Hamaguchi T, Mizuno T, Shirao K (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMed Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M, Hamaguchi T, Mizuno T, Shirao K (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMed
10.
go back to reference Currow DC, Plummer J, Frith P, Abernethy AP (2007) Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 10:1031–1036CrossRefPubMed Currow DC, Plummer J, Frith P, Abernethy AP (2007) Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 10:1031–1036CrossRefPubMed
11.
go back to reference Currow DC, Rowett D, Doogue M, To TH, Abernethy AP (2012) An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 15:282–286. doi:10.1089/jpm.2012.9605 PubMed Currow DC, Rowett D, Doogue M, To TH, Abernethy AP (2012) An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 15:282–286. doi:10.​1089/​jpm.​2012.​9605 PubMed
12.
13.
go back to reference Matsuo N, Morita T, Matsuda Y, et al. Predictors of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: A multicenter prospective observational study. J Pain Symptom Manage. In press Matsuo N, Morita T, Matsuda Y, et al. Predictors of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: A multicenter prospective observational study. J Pain Symptom Manage. In press
14.
go back to reference Selby D, Cascella A, Gardiner K, Do R, Moravan V, Myers J, Chow E (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton symptom assessment system. J Pain Symptom Manag 39:241–249. doi:10.1016/j.jpainsymman CrossRef Selby D, Cascella A, Gardiner K, Do R, Moravan V, Myers J, Chow E (2010) A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton symptom assessment system. J Pain Symptom Manag 39:241–249. doi:10.​1016/​j.​jpainsymman CrossRef
16.
go back to reference Lundström SH, Fürst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437CrossRefPubMed Lundström SH, Fürst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437CrossRefPubMed
17.
go back to reference Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, Stone P (2001) A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 15:3–8CrossRefPubMed Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, Stone P (2001) A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 15:3–8CrossRefPubMed
18.
go back to reference Mercadante S, Fulfaro F, Casuccio A (2001) The use of corticosteroids in home palliative care. Support Care Cancer 9:386–389CrossRefPubMed Mercadante S, Fulfaro F, Casuccio A (2001) The use of corticosteroids in home palliative care. Support Care Cancer 9:386–389CrossRefPubMed
19.
go back to reference Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson symptom inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRef Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson symptom inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRef
20.
go back to reference Morita T, Tsunoda J, Inoue S, Chihara S (1999) Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manag 18:2–3CrossRef Morita T, Tsunoda J, Inoue S, Chihara S (1999) Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manag 18:2–3CrossRef
21.
go back to reference Miyashita M, Matoba K, Sasahara T, Kizawa Y, Maruguchi M, Abe M, Kawa M, Shima Y (2004) Reliability and validity of the Japanese version of the support team assessment schedule (STAS-J). Palliat Support Care 2:379–385CrossRefPubMed Miyashita M, Matoba K, Sasahara T, Kizawa Y, Maruguchi M, Abe M, Kawa M, Shima Y (2004) Reliability and validity of the Japanese version of the support team assessment schedule (STAS-J). Palliat Support Care 2:379–385CrossRefPubMed
22.
go back to reference American Psychiatric Association (2000) Mood Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, pp 369–382 American Psychiatric Association (2000) Mood Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, pp 369–382
23.
go back to reference Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, Danjoux C, Barnes E, Sahgal A, Poon M, Chow E (2013) Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. J Pain Symptom Manag 46:192–200. doi:10.1016/j.jpainsymman.2012.07.022 CrossRef Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, Danjoux C, Barnes E, Sahgal A, Poon M, Chow E (2013) Minimal clinically important differences in the Edmonton symptom assessment system in patients with advanced cancer. J Pain Symptom Manag 46:192–200. doi:10.​1016/​j.​jpainsymman.​2012.​07.​022 CrossRef
24.
go back to reference Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, Park M, Yennu S, Kang JH, Bruera E (2015) Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicenter study. Cancer 121:3027–3035. doi:10.1002/cncr.29437 CrossRefPubMedPubMedCentral Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, Park M, Yennu S, Kang JH, Bruera E (2015) Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicenter study. Cancer 121:3027–3035. doi:10.​1002/​cncr.​29437 CrossRefPubMedPubMedCentral
25.
go back to reference Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.1200/JCO.2012.44.4661 CrossRefPubMed Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076–3082. doi:10.​1200/​JCO.​2012.​44.​4661 CrossRefPubMed
26.
go back to reference Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, Kaasa S (2014) Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 32:3221–3228. doi:10.1200/JCO.2013.54.3926 CrossRefPubMed Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, Kaasa S (2014) Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 32:3221–3228. doi:10.​1200/​JCO.​2013.​54.​3926 CrossRefPubMed
29.
go back to reference Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 22:1957–1965CrossRefPubMed Akechi T, Okuyama T, Sugawara Y, Nakano T, Shima Y, Uchitomi Y (2004) Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 22:1957–1965CrossRefPubMed
Metadata
Title
Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study
Authors
Naoki Matsuo
Tatsuya Morita
Yoshinobu Matsuda
Kenichiro Okamoto
Yoshihisa Matsumoto
Keisuke Kaneishi
Takuya Odagiri
Hiroki Sakurai
Hideki Katayama
Ichiro Mori
Hirohide Yamada
Hiroaki Watanabe
Taro Yokoyama
Takashi Yamaguchi
Tomohiro Nishi
Akemi Shirado
Shuji Hiramoto
Toshio Watanabe
Hiroyuki Kohara
Satofumi Shimoyama
Etsuko Aruga
Mika Baba
Koki Sumita
Satoru Iwase
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3383-z

Other articles of this Issue 1/2017

Supportive Care in Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine